Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 September 2018 Photo Lerato Moloi
New Principal for Qwaqwa Campus-Dr Matin Mandew
Dr Martin Mandew believes that the biggest challenge currently facing the higher-education sector is the lack of adequate and appropriate student housing


The University of the Free State (UFS) Qwaqwa Campus has a new Principal. He is Dr Martin Mandew, former Campus Director of the Durban University of Technology’s Midlands Campus in Pietermaritzburg. He has extensive experience in higher education, having cut his teeth in the academia as an Academic Development Tutor with the then University of Natal (now University of Kwazulu-Natal). He then went on to complete both his Master of Theology (cum laude) and Doctor of Philosophy at the same institution in 1993 and 1997, respectively.

“During my early days in the academia, we did some interesting educational experiments and pioneered exciting foundation programmes. I also taught Systematic Theology in the mainstream programme,” said Dr Mandew, a trained Catholic theologian holding a Bachelor of Sacred Theology (magna cum laude) from the Urbaniana Pontifical University in Rome, Italy.

His academic interest shifted after he was appointed as Assistant Vice-Chancellor: Student Services at the ML Sultan Technikon in 1998. “My time at ML Sultan helped me develop a keen interest in the theoretical foundations and practice in the field of student services and affairs. This interest abides to this day,” he said.

Coming from a multi-campus background, what challenges does he think the UFS would be better placed to avoid?


“Multi-campus universities have their own unique challenges. However, what often seems to be a frequently recurring issue, is the sense of disconnectedness often felt by the far-flung smaller campuses. This can be overcome through regular contact – real and virtual – between the campuses through senior leaders and managers, and through a structured exchange of academics and lecturers between the campuses,” said Dr Mandew, who was born and brought up in the multilingual and multicultural neighbourhood of Aliwal North in the Eastern Cape.

He believes the biggest challenge currently facing the higher-education sector, is the lack of adequate and appropriate student housing.

“This problem is worse at rural campuses such as Qwaqwa where there is a scarcity of private accommodation that meets the norms and standards as prescribed by the Department of Higher Education and Training (DHET). We have to find ways of persuading private student-accommodation providers to invest in the provision of accommodation that meets the prescribed norms. This is not only their civic duty, as there is a return to be had on the investment.”

“A related challenge,” he added, “is how to better integrate commuting or day students, who constitute the majority of our students, in university life. We have to design co-curricular programmes that reach the wider student body and invest in the establishment of day houses to better respond to the needs of commuting students.”

What is his vision for the campus and what are his first impressions of the broader UFS?

“I have been very impressed by some of the important, though very difficult conversations currently taking place at the UFS. Like other universities, the UFS has to find effective ways to contend with the scourge of gender-based violence. I hope we can succeed in finding practical ways to put the Integrated Transformation Plan (ITP) at the centre of our endeavours in Qwaqwa, in order to realise this rather exciting and challenging vision. Needless to say, students have to be at the centre of these endeavours,” he emphasised.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept